Overview

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability to CKD-519 new formulation in healthy male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical